Pseudohyperplastic Prostatic Adenocarcinoma: A Case Report and Review of the Literature +



Similar documents
GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma

A918: Prostate: adenocarcinoma

Early Prostate Cancer: Questions and Answers. Key Points

Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: Urologic Pathologists

Prostate Cancer In-Depth

PCA3 DETECTION TEST FOR PROSTATE CANCER DO YOU KNOW YOUR RISK OF HAVING CANCER?

Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Something Old, Something New.

Diagnostic Challenge. Department of Pathology,

The Diagnosis of Cancer in the Pathology Laboratory

ATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA

Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!

HEALTH NEWS PROSTATE CANCER THE PROSTATE

KIDNEY CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATION / TFE3 (ASPL-TFE3) GENE FUSION

MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER

Single Prostatic Cancer Foci on Prostate Biopsy

Case presentation: Mesothelioma of the tunica vaginalis. Dr Ben Shepherd Pathology Queensland Princess Alexandra Hospital Brisbane

Us TOO University Presents: Understanding Diagnostic Testing

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

Classificazioni citologiche: verso uno schema internazionale unificato?

CMScript. Member of a medical scheme? Know your guaranteed benefits! Issue 7 of 2014

Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports

7. Prostate cancer in PSA relapse

1. What is the prostate-specific antigen (PSA) test?

Histopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy

Cancer doesn t care but we do Cancer Annual Report

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date

Prostate Specific Antigen (PSA) Blood Test

Frozen Section Diagnosis

The Use of Immunohistochemistry for Diagnosis of Prostate Cancer

Cytopathology Case Presentation #8

Your bladder cancer diary. WA Cancer and Palliative Care Network

Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives.

PATIENT GUIDE. Localized Prostate Cancer

An Introduction to PROSTATE CANCER

YOUR LUNG CANCER PATHOLOGY REPORT

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Historical Basis for Concern

Guidelines for reporting histopathology of cervical carcinoma

A 70-year old Man with Pleural Effusion

Prostate Cancer Screening. Dr. J. McCracken, Urologist

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

OBJECTIVES By the end of this segment, the community participant will be able to:

CONTENTS: WHAT S IN THIS BOOKLET

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1

Cystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer.

Today s Topics. Tumors of the Peritoneum in Women

Diagnosis of Prostatic Carcinoma After Therapy

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet

Prostate Cancer. Patient Information

Histopathology of Major Salivary Gland Neoplasms

Update on Mesothelioma

Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer

Effusions: Mesothelioma and Metastatic Cancers

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14

For further information on screening and early detection of prostate cancer, see the Section entitled Screening for Prostate Cancer.

Appendix 2. Patient information

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

SEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS

PSA Screening for Prostate Cancer Information for Care Providers

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

SIGNPOSTS. Along the Pathway of Prostate Cancer. Understanding Diagnostic Tests and Procedures to Monitor Prostate Cancer

BRAF in the diagnostic evaluation of thyroid nodules

Histologic Subtypes of Renal Cell Carcinoma

TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD

LIvING WITH Prostate Cancer

The develpemental origin of mesothelium

Tubulocystic Carcinoma of the Kidney, a Rare Distinct Entity

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

Policy Wording. Together, all the way.

Prostate Cancer. What is cancer?

The Benign Endometrial Hyperplasia Sequence

Localized Prostate Cancer

Ovarian mucinous lesions. Ovarian mucinous lesions: Common diagnostic dilemmas. Ovarian mucinous lesions: problematic issues

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

R-16: Chronic nonspecific cervisit

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH

Prostate Cancer. There is no known association with an enlarged prostate or benign prostatic hyperplasia (BPH).

How is Prostate Cancer Diagnosed?

Prostate Cancer in Older Men

Treatment of Incidental Prostate Cancer Diagnosed during BPH Surgery with Radical Prostatectomy: Appropriate or over Treatment?

Immunohistochemical differentiation of metastatic tumours

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Pathology of lung cancer

PROTOCOL OF THE RITA DATA QUALITY STUDY

Medullary Renal Cell Carcinoma Case Report

Does my patient need more therapy after prostate cancer surgery?

Explanation of your PAP smear

Transcription:

İnönü Üniversitesi Tıp Fakültesi Dergisi 13(4) 263-267 (2006) Pseudohyperplastic Prostatic Adenocarcinoma: A Case Report and Review of the Literature + Aysegül Sarı*, Murat Ermete*, Aylin Callı*, Fikret Sengül** *Ataturk Training and Research Hospital, Department of Pathology, İzmir **Ataturk Training and Research Hospital, Department of 2 nd Urolgy, Izmir Pseudohyperplastic adenocarcinoma is a recently described rare type of prostatic adenocarcinoma with deceptively benign architectural features. Pseudohyperplastic pattern mimics benign glands owing to their papillary infoldings,luminal indulations, large size and occasional corpora amylacea. The main morphologic features helpful in establishing the malignancy are; nuclear enlargement, occasional to frequent nucleoli and total absence of basal cells. The diagnostic significance of this pattern lies in its potential to be misdiagnosed as benign prostate glands and adenosis. Herein we report a case of a pseudohyperplastic carcinoma and a brief review of the literature. Key Words: Pseudohyperplastic prostatic adenocarcinoma, Gleason grade, Prostate cancer Psödohiperplastik Prostat Adenokarsinomu: Olgu Sunumu Psödohiperplastik prostat adenokarsinomu aldatıcı olarak benign arşitektürel özelliklere sahip bezlerle karakterize, prostat adenokarsinomunun son yıllarda tanımlanmış nadir bir varyantıdır. Psödohiperplastik patern, papiller katlantıları ve luminal düzensizlikleri olan geniş çaplı, arada corpora amylocea içeren bezler nedeniyle benign bezleri andırır. Nükleer irileşme, arada izlenebilen nükleol belirginliği ve bazal hücrelerin tamamen kaybı maligniteyi destekleyen morfolojik bulgulardır. Bu paternin bilinmesi ve tanınması, psödohiperplastik prostat adenokarsinomun, benign prostat bezleri ya da adenozis olarak yanlış tanı alma potansiyelinin bulunması nedeniyle önemlidir. Anahtar Kelimeler: Psödohiperplastik prostat adenokarsinomu, Gleason grade, Prostat kanseri + This article was presented in poster format in 18 th National Oncologic Pahtology Symposium, (Çeşme- Altınyunus, May, 2006.) Pseudohyperplastic adenocarcinoma (PHPA) is a recently described type of adenocarcinoma which is characterized by back to-back arranged large glands with branching and papillary infoldings that simulate benign hyperplastic glands. The deceptively benign architectural features make this pattern of prostate cancer difficult to diagnose. 1 Nuclear enlargement with macronucleoli observed in some of these glands and complete lack of basal cells are the morphologic features that help to establish the malignant nature of the lesion. Therefore the diagnosis of PHPA is based upon a constellation of findings which include crowded glands, architectural hyperplastic pattern, atypical cytology and lack of basal cells by immunohistochemistry. 1,2 We report a case of a PHPA in transurethral (TUR) prostate specimen of a 55 year old man with initial clinical diagnoses of benign prostatic hyperplasia and review the literature. CASE REPORT 76 year old man presented with dysuria, inconsistency and urgency of approximately one year duration. 6 months prior to this admission he had urinary catherization for 15 days because of urinary retention and then he was given alpha- adrenergic blocker (Flomax) which didn t stop his symptoms. On his second admission, digital rectal examination revealed grade1 benign prostate enlargement. Laboratory examinations revealed normal urine microscopy and culture and serum prostate- specific antigen measured 2.4 ng/ml. Transurethral resection (TUR) of the prostate was performed and sent to pathology department with initial diagnosis of benign glandular hyperplasia. All of the tissue samples underwent histological examination which was composed of a total of 190 263

Sarı ve ark chips. Microscopically at low power magnification, in 9 fragments, crowded glands, with papillary infoldings, branching and luminal indulations and occasional cystic glands associated with or without papillary infoldings were observed, comprising a length of between 2 to 5mm (figure 1,2,3). Some of the glands had corpora amylocea or pink amorphous secretions in their lumens. These foci of hyperplastic glands were partially well circumscribed resembling either benign glandular hyperplasia or adenosis at low magnification. In some foci, minimal extension of neoplastic glands into the nonneoplastic prostate was observed (figure 2). High power examination for nuclear features revealed rare to frequent prominent nucleoli, nucleomegali, hyperchromasia and scarce mitotic figures (figure 1). Basal cells of all these hyperplastic glands failed to show immunoreactivity for high molecular weight cytokeratin (figure 3). The case was reported as adenocarcinoma of prostate with Gleason grade 2+2 with a total Gleason score of 4. Because of his advanced age and poor general condition, instead of radical surgery it was decided that the patient should be followed up with serial PSA measurements at 6 months intervals. Antiandrogens and radiotherapy was not considered as a treatment option as it was an incidentally found tumor on TUR- prostate for BPH and it was a low clinical stage disease with low gleason score and low PSA levels. The patient s PSA levels were within normal limits at his first control. in 2 of 100 (2%) cases in needle biopsies and 22 of 202 (11%) cases in radical prostatectomy. In needle biopsies 5% and 24% of the total cancer length revealed pseuodohyperplastic foci and in radical prostatectomies pseudohyperplastic areas comprised 0,9-33% of total tumor size. They observed that hyperplastic alterations were in continuity with prostatic carcinomas and these carcinomas were of lower Gleason score (median Gleason score 5) in contrast to carcinomas without pseudohyperplastic change ( median Gleason score 6). However, they failed to find pathologic stage differences in these two groups and concluded that the diagnostic significance of this pattern only lied in its potential to be misdiagnosed as benign, usual hyperplasia. 2 Figure 1a. Crowded glands with papillary infoldings, luminal indulations and branching. The differential diagnosis is between pseudoyperplastic adenocarcinoma and adenosis. DISCUSSION Prostatic adenocarcinoma mimicking benign processes has long been known, and article by Muir 3 was the first one to mention the diagnostic difficulty of prostatic adenocarcinoma resembling hyperplastic appearing benign glands. However it is claimed that the only illustration of his article related to this comment was of a typical adenocarcinoma with a Gleason score of 3+3=6. 1 Pseudohyperplastic change in prostate cancer was first described and illustrated by Epstein in1989 4 but it has not been studied as a specific histologic variant. So far the main morphologic features and frequency of this neoplasm has been studied in limited number of reports. 1,2,5 Figure 1b. High power magnification demonstrates columnar cells with basally located nucleus demonstrating marked cytologic atypia with nuclear enlargement and prominent macronucleoli consistent with adenocarcinoma The term Pseudohyperplastic prostatic adenocarcinoma was first used by Humphrey et al.in1998. 2 They reviewed 302 cases of prostatic adenocarcinoma including 100 consecutive prostatic needle biopsies and 202 radical prostatectomy specimens. Pseudohyperplastic changes were present 264

Pseudohyperplastic Prostatic Adenocarcinoma: A Case Report and Review of the Literature Figure 2a. Nodular growth pattern of neoplastic glands with cystic dilatation and papillary infoldings. Some contain corpora amyleocea and pink amourpous secretions. Transition to small aciner pattern of adenocarcinoma is present. Figure3b. High-molecular cytokeratin stain shows total absence of basal cell layer in crowded glands whereas basal cell layer of benign glands is intensely positive. Figure 2b. Higher magnification shows that these glands lack prominent nucleoli but nuclear enlargement and scarce mitotic figures are present. Figure 3a. Focus of crowded glands which resemble benign glandular hyperplasia with their large size and papillary infoldings. Later on for defining better the histopathologic features of PHPA ; Levi and Epstein investigated 16 needle biopsy and 4 simple prostatectomy specimens in which the majority of the cancer (at least 60%- and in most cases, 90%) was pseudohyperplastic 1. Within these pseudohyperplastic foci nuclear enlargement, pink amorphous secretions, occasional to frequent nucleoli, crystalloids and lack of basal cells were the important histopathologic features in establishing the malignant diagnosis 1 (table 1). Arista- Nasr et al. examined histopathologic features (table1) and frequency of PHPA in transurethral resections. 5 They studied 150 specimens originally diagnosed as benign hyperplasia and 100 as conventional prostatic adenocarcinomas. Two (%1,3) of the benign TUR specimens were found to have PHPA in which the neoplasm was limited to two chips and measured 3 and 4 mm, respectively. Areas of PHPA was present in only three cases of the 100 biopsies with adenocarcinomas and found in two fragments in two cases, three fragments in one case and measured 3,4 and 6 mm respectively. Average of 115 fragments were analyzed in each biopsy. 5 In our case PHPA was present in 9 chips out of 190 fragments comprising a length between 2 to 5mm and was associated with transition to small aimer pattern of prostatic adenocarcinma in some foci. Main histologic findings in low power magnification were crowded glands with papillary infoldings, luminal indulations, branching and occasional cystic glands some of which contained corpora amylacea and pink amorphous secretions. Nuclear enlargement with rare to prominent macronucleoli and scarce mitotic figures detected in high power magnification helped to establish malignancy supported by the lack of basal cells with high molecular weight cytokeratin (hmwck). 265

Sarı ve ark Other features of malignancy such as blue mucin, cyrstalloids, adjacent prostatic intraepithelial neoplasia (PIN) or perineural invasion was not present. As PHPA shares common features with benign glandular hyperplasia and is found in small and isolated areas, it wouldn t be unusual for this pattern of adenocarcinoma to be overlooked when analyzing TUR specimens. However percentage of false negative results (1,3%) appears to be infrequent according to the only study conducted on the frequency of PHPA in TUR specimens. 5 Considering the findings of Humphrey et al., who found that the pseudohyperplastic change consisted only 6% of tumor size in radical prostatectomies, it is not suprising to encounter PHPA in small amounts in TUR specimens. 2,5 In low power magnification apart from a focus of crowded glands, only minority of the cases reported in the literature had diagnostically helpful features of malignancy such as crystalloids, blue mucin, intraluminal pink material and perineural invasion which urges high-magnification scrutiny for nuclear enlargement, prominent nucleoli and absence of basal cells (table 1). Therefore hyperplastic pattern must be suspected in low power microscopy 6 and due to difficulties in diagnosing these lesions on hematoxylin-and eosin stained sections, it is almost always helpful to confirm diagnosis with the use of immunohistochemistry to verify the absence of basal cells. 1,6-8 Table 1. Frequency of histologic features, literature findings Histologic feature No.cases* No.cases** No.cases*** Papillary projections 22/22 20/20 5/5 Branching glands 11/22 9/20 1/5 Nuclear enlargement 22/22 19/20 5/5 Clear epithelium 19/22 N/A 5/5 Columnar epithelium 21/22 N/A 5/5 Macronucleoli 22/22 9/20 4/5 Large/Cystic glands 7/22 19/20 4/5 Straight luminal borders N/A 4/20 4/5 Pink amorphous secretions 6/22 14/20 4/5 Nuclear hyperchromasia N/A 3/20 3/5 Transition to small acinar ca 19/22 N/A 3/5 Infiltrative growth 6/22 5/20 0/5 Corpora amylacea N/A 4/20 2/5 Mitotic figures 6/22 0/20 1/5 Blue mucin 3/22 3/20 0/5 Cyristaloids 8/22 9/20 0/5 Perineural invasion 2/22 1/20 0/5 Colleganeous micronodules 0/22 0/20 0/5 Glomerulations N/A 0/20 0/5 Associated PIN 11/22 4/20 0/5 Absent basal cells 22/22 20/20 5/5 *Humprey et all ( 2 ), **Levi and Epstein ( 1 ), ***Arista-Nasr et al.( 5 ) N/A: not available High grade PIN could resemble PHPA but PIN would not be as crowded or as infiltrative and maintains basal cells in varying proportions. 1,5 Although the Gleason scoring system did not account for this histologic pattern, 1,5 it was the consensus of the panel in the international consensus conference of Gleason grading system update that these tumors should be graded as Gleason score 3+3=6 as they were most often accompanied by the more typical 3+3=6 prostatic adenocarcinoma. 9 Without knowing this information, we graded our case as Gleason patern 2+2 (with a total Gleason score of 4) since neoplastic glands were partially well circumbsribed. We don t know whether gleason grade 3+3 adenocarcinoma was present in the rest of the prostat tissue, since radical prostatectomy was not performed in our patient. The clinical course of PHPA is not well known due to insufficient literature regarding patient prognoses. Extraprostatic extension and seminal vesicle invasion was idendified in four cases by Levi and Epstein who suggested that this variant should not be considered as a low-grade cancer. 1 In the study of Arista- Nastr et al., two cases with small fragments of PHPA initially diagnosed as benign glandular hyperplasia had favorable clinical course of 2 and 4 years after diagnosis; but in the other two cases where PHPA represented a lower percentage of the neoplasm and was associated with moderately or poorly differentiated prostatic adenocarcinoma, unfavorable clinical course was detected with metastasis. 5 Additional studies are needed not only to accurately grade the pseudoyperplastic pattern of prostatic adenocarcinoma but also to predict the patient prognosis. Limited data suggests that PHPA has potential to exhibit agressive behaviour. Nevertheless high degree of diagnostic awareness is required not to underdiagnose PHPA as a benign process due to the rarity of its presentation, deceptively benign architectural features and its potential to present unfavorable prognosis. REFERENCES 1. Levi AW, Epstein JI. Pseudohyperplastic prostatic adenocarcinoma on needle biopsy and simple prostatectomy. Am J Surg Pathol 2000;24(8):1039-46. 2. Humphrey PA, Kaleem Z, Swanson PE, Vollmer RT. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol 1998;22(10):1239-46. 3. EG Muir. Carcinoma of the prostate. Lancet 1934;1:667-72. 4. Epstein JI. Variants of prostatic adenocarcinoma In:Prostat biopsy interpretation, New York. NY: Lippincott- Raven, 1989:169-73 5. Arista-Nasr J, Martinez-Benitez B, Valdes S, Hernandez M, Bornstein-Quevedo L. Pseudohyperplastic prostatic adenocarcinoma in transurethral resections of the prostate. Pathol Oncol Res 2003;9(4):232-5. 6. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. AFIP Atlas of Tumor Pathology, Third Series, Fascicle 28, Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis pg 140, 2000. 266

Pseudohyperplastic Prostatic Adenocarcinoma: A Case Report and Review of the Literature 7. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): WHO Classification of Tumors, Pathology and Genetics of Tumours of Urinary System and Male Genital Organs, IARC Press: Lyonn. pg 160-192, 2004. 8. Epstein JI, Young XJ. Prostate biopsy interpretation, Lippincott Williams and Wilkins, 3 rd edition, pg 64-91, 2002. 9. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. Update on the Gleason Grading System for Prostate Cancer: Results of an International Consensus Conference of Urologic Pathologists. Adv Anat Pathol 2006;13(1):57-9. Address for correspondence: Dr. Ayşegül Sarı, Akder Eczanesi 1391 sokak, No:4/B, Alsancak, Izmir, TURKEY Phone : 232 244 4444-2686 Fax : 232 464 5308 E-mail : aysegulakder@gmail.com 267